Rodriguez P et al., 2017-06: Companion randomized, double-blind, placebo-controlled imaging study in 28 healthy adults given a single 280 mg oral dose of methylene blue or placebo. Methylene blue was associated with reduced task-related cerebral blood flow and stronger resting-state functional connectivity; no behavioural or cognitive outcome was measured.
Twenty-eight participants were enrolled between September 2013 and December 2014, and randomized to 280 mg of oral USP grade methylene blue (methylthioninium chloride, PCCA, Houston, Texas) or placebo (FD&C Blue #2) after completing baseline fMRI tasks.
Rodriguez P et al., 2017-06: Companion randomized, double-blind, placebo-controlled imaging study in 28 healthy adults given a single 280 mg oral dose of methylene blue or placebo. Methylene blue was associated with reduced task-related cerebral blood flow and stronger resting-state functional connectivity; no behavioural or cognitive outcome was measured. Study type: randomized double-blind placebo-controlled trial, imaging only. N=28 enrolled (15 MB / 13 placebo). Dose 280 mg oral MB USP, single dose, selected as ~4 mg/kg for 70 kg. Country: USA. Funder: pilot grant under UL1TR001120, National Center for Advancing Translational Sciences (NIH). Declared conflicts: 'All authors report no competing interests.' The paper states its own limitation: 'The lack of behavioral scores for this study is also a limitation'. Nothing here measures memory, attention or mental clarity, so it cannot support a cognitive-benefit claim on its own. Also filed as MTC-055, MTK-02 (claims C1, C9). Study type: randomized trial.
